Immuron Share Price Today
(NASDAQ: IMRN)

Name: Immuron Share Price Today (NASDAQ: IMRN) - Immuron Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Immuron share price is $1.9 & ₹165.24 as on 6 Mar 2025, 2.30 'hrs' IST

$1.9

▲

0.14

(8.2%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Immuron share price in Dollar and Rupees. Guide to invest in Immuron stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Immuron, along with analyst recommendations, forecasts, and comprehensive financials.

Immuron share price movements

Today's Low: $1.80
Today's High: $1.99
$1.90
5.26%
Downside
Day's Volatility :9.54%
Upside
4.52%
52 Weeks Low: $1.70
52 Weeks High: $5.96
$1.90
10.53%
Downside
52 Weeks Volatility :71.48%
Upside
68.12%

Immuron (IMRN) Returns

Period	Immuron Ltd	Index (Russel 2000)
3 Months	-13.07%	0.0%
6 Months	-32.72%	0.0%
1 Year	-61.41%	0.0%
3 Years	-35.2%	-11.6%

Immuron (IMRN) Key Statistics

in dollars & INR

Previous Close	$1.756
Open	$1.9899
Today's High	$1.9899
Today's Low	$1.8
Market Capitalization	$11.2M
Today's Volume	$1.1K
52 Week High	$5.96
52 Week Low	$1.7
Revenue TTM	$6.5M
EBITDA	$-5.7M
Earnings Per Share (EPS)	$-0.77
Profit Margin	-112.4%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-52.77%

How to invest in Immuron Stock (IMRN) from India?

It is very easy for Indian residents to invest directly in Immuron from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Immuron stock in both Indian Rupees (INR) and US Dollars (USD). Search for Immuron or IMRN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Immuron or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Immuron shares which would translate to 0.458 fractional shares of Immuron as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Immuron, in just a few clicks!

Returns in Immuron (IMRN) for Indian investors in Rupees

The Immuron stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Immuron investment value today

Current value as on today

₹46,721

Returns

₹53,279

(-53.28%)

Returns from Immuron Stock

₹58,242 (-58.24%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Immuron (IMRN)

-55%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Immuron Stock from India on INDmoney has decreased by -55% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immuron

Rhumbline Advisers
0.10%

Analyst Recommendation on Immuron

Analyst Forecast on Immuron Stock (IMRN)

What analysts predicted

Upside of 145.07%

Target:

$4.66

Current:

$1.90

Insights on Immuron Stock (Ticker Symbol: IMRN)

Price Movement
In the last 7 days, IMRN stock has moved down by -10.2%
IMRN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 55.9%
IMRN vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 86.1%
Price to Sales
ForIMRN every $1 of sales, investors are willing to pay $1.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

IMRN Immuron Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$1.7M	↑ 29.55%
Net Income	$-3.2M	↑ 54.26%
Net Profit Margin	-194.55%	↓ 31.17%

	FY20	Y/Y Change
Revenue	$1.7M	↑ 5.49%
Net Income	$-2.0M	↓ 37.46%
Net Profit Margin	-115.33%	↑ 79.22%

	FY21	Y/Y Change
Revenue	$111.3K	↓ 94.21%
Net Income	$-6.4M	↑ 188.64%
Net Profit Margin	-5.8K%	↓ 5636.28%

	FY22	Y/Y Change
Revenue	$537.9K	↑ 424.91%
Net Income	$-2.0M	↓ 65.96%
Net Profit Margin	-373.01%	↑ 5378.6%

	FY23	Y/Y Change
Revenue	$1.2M	↑ 135.85%
Net Income	$-2.5M	↑ 32.66%
Net Profit Margin	-209.81%	↑ 163.2%

	FY24	Y/Y Change
Revenue	$3.3M	↑ 171.67%
Net Income	$-4.6M	↑ 83.2%
Net Profit Margin	-141.49%	↑ 68.32%

	Q4 FY22	Q/Q Change
Revenue	$393.9K	-
Net Income	$-1.3M	-
Net Profit Margin	-338.97%	-

	Q1 FY23	Q/Q Change
Revenue	$407.8K	↑ 4.61%
Net Income	$-603.9K	↓ 54.3%
Net Profit Margin	-148.08%	↑ 190.89%

	Q2 FY23	Q/Q Change
Revenue	$820.3K	↑ 100.0%
Net Income	$-1.2M	↑ 100.0%
Net Profit Margin	-148.08%	↑ 0.0%

	Q4 FY23	Q/Q Change
Revenue	$2.4M	↑ 92.91%
Net Income	$-2.1M	↑ 14.66%
Net Profit Margin	-88.01%	↑ 60.07%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 8.14%
Net Income	$-4.9M	↑ 134.6%
Net Profit Margin	-190.94%	↓ 102.93%

	Q3 FY24	Q/Q Change
Revenue	$2.5M	↑ 0.0%
Net Income	$-4.9M	↑ 0.0%
Net Profit Margin	-190.94%	↑ 0.0%

	FY19	Y/Y Change
Profit	$1.2M	↑ 76.87%

	FY20	Y/Y Change
Profit	$1.3M	↑ 6.38%

	FY21	Y/Y Change
Profit	$72.3K	↓ 94.82%

	FY22	Y/Y Change
Profit	$368.0K	↑ 452.77%

	FY23	Y/Y Change
Profit	$879.5K	↑ 150.07%

	FY24	Y/Y Change
Profit	$2.2M	↑ 154.88%

	Q4 FY22	Q/Q Change
Profit	$288.8K	-

	Q1 FY23	Q/Q Change
Profit	$377.4K	↑ 32.03%

	Q2 FY23	Q/Q Change
Profit	$592.0K	↑ 55.97%

	Q4 FY23	Q/Q Change
Profit	$1.6M	↑ 79.33%

	Q2 FY24	Q/Q Change
Profit	$1.8M	↑ 11.14%

	Q3 FY24	Q/Q Change
Profit	$1.8M	↑ 0.0%

	FY19	Y/Y Change
Operating Cash Flow	$-1.2M	↓ 49.01%
Investing Cash Flow	$-1.4K	↓ 62.23%
Financing Cash Flow	$1.4M	↓ 52.68%

	FY20	Y/Y Change
Operating Cash Flow	$-2.2M	↑ 74.99%
Investing Cash Flow	$-595.0	↓ 56.97%
Financing Cash Flow	$798.0K	↓ 44.09%

	FY21	Y/Y Change
Operating Cash Flow	$-3.1M	↑ 29.74%
Investing Cash Flow	$2.0K	↓ 397.92%
Financing Cash Flow	$20.2M	↑ 2189.98%

	FY22	Y/Y Change
Operating Cash Flow	$-2.2M	↓ 23.29%
Investing Cash Flow	$8.3K	↑ 355.98%
Financing Cash Flow	$-25.5K	↓ 100.14%

	FY23	Y/Y Change
Operating Cash Flow	$-1.7M	↓ 20.55%
Investing Cash Flow	$-1.8M	↓ 22433.47%
Financing Cash Flow	$-23.5K	↓ 3.44%

	Q4 FY22	Q/Q Change
Operating Cash Flow	$-636.1K	↑ 90.01%
Investing Cash Flow	$-878.6K	↑ 0.0%
Financing Cash Flow	$-11.5K	↑ 58.11%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-535.4K	↓ 14.95%
Investing Cash Flow	$-5.9K	↓ 99.32%
Financing Cash Flow	$-7.7K	↓ 31.82%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-1.0M	↑ 92.88%
Investing Cash Flow	$-5.9K	↑ 0.0%
Financing Cash Flow	$-12.1K	↑ 55.54%

Immuron Technicals Summary

Sell

Neutral

Buy

Immuron is currently in a neutral trading position according to technical analysis indicators.

Immuron (IMRN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immuron Ltd	-11.31%	-32.72%	-61.41%	-35.2%	-32.54%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immuron Ltd	NA	NA	0.0	0.0	-0.53	-0.22	NA	0.05
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immuron Ltd	NA	$11.2M	-32.54%	NA	-112.4%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Organization	Immuron
Employees	7
CEO	Mr. Steven George Lydeamore CPA, M.B.A.
Industry	Health Technology

Management People of Immuron

Name	Title
Mr. Steven George Lydeamore CPA, M.B.A.	Chief Executive Officer
Dr. Jerry Kanellos Ph.D.	Chief Operating Officer
Mr. Flavio Palumbo	Chief Commercial Officer
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO & Company Secretary
Mr. David Lyon	Head of Marketing

Important FAQs about investing in IMRN Stock from India :

What is Immuron share price today?

Immuron share price today stands at $1.90, Open: $1.99 ; Previous Close: $1.76 ; High: $1.99 ; Low: $1.80 ; 52 Week High: $5.96 ; 52 Week Low: $1.70.

The stock opens at $1.99, after a previous close of $1.76. The stock reached a daily high of $1.99 and a low of $1.80, with a 52-week high of $5.96 and a 52-week low of $1.70.

Can Indians buy Immuron shares?

Yes, Indians can invest in the Immuron (IMRN) from India.

With INDmoney, you can buy Immuron at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Immuron at zero transaction cost.

How can I buy Immuron shares from India?

It is very easy to buy Immuron from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Immuron (IMRN) be purchased?

Yes, you can buy fractional shares of Immuron with INDmoney app.

What are the documents required to start investing in Immuron stocks?

To start investing in Immuron, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.